文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

结核分枝杆菌耐药检测:挑战、进展与展望

Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.
PubMed 文献 · Clin Microbiol Infect · 2016-11-01

本文综述了结核分枝杆菌耐药检测的表型与基因型方法。表型方法常用于高收入国家确认新病例敏感性,基因型方法在低收入国家因免培养更易开展。两种方法互补可提高检测准确性,但目前缺乏MIC测定的共识参考方法。

要点

  • 表型与基因型药敏试验互补,可提高耐药检测敏感性和特异性。
  • 基因型方法可快速检测热点突变,但需警惕假耐药和假敏感结果。
  • 目前尚无MIC测定的共识参考方法,影响未来抗结核药物评估。

核心结论

  • 表型与基因型药敏方法互补,可提高耐药检测准确性并预测MDR/XDR治愈。

研究设计与样本

  • 综述,回顾结核分枝杆菌表型与基因型药敏检测的不同方法与技术。

主要发现

  • 高收入国家常用培养法表型药敏确认新病例敏感性,并结合基因型检测高危病例耐药。
  • 低收入国家基因型方法因免培养和生物安全限制更易开展。
  • 基因型检测可快速识别rpoB突变等主要耐药机制,但存在假耐药和假敏感结果。

临床怎么用

  • 根据资源条件选择表型或基因型药敏方法,联合使用以提高检测准确性。
  • 基因型结果需警惕假耐药与假敏感,必要时结合表型确认。

局限性

  • 自1960年代建立药敏试验以来,尚无MIC测定的共识参考方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-resistance testing, or antimicrobial susceptibility testing (AST), is mandatory for Mycobacterium tuberculosis in cases of failure on standard therapy. We reviewed the different methods and techniques of phenotypic and genotypic approaches. Although multiresistant and extensively drug-resistant (MDR/XDR) tuberculosis is present worldwide, AST for M. tuberculosis (AST-MTB) is still mainly performed according to the resources available rather than the drug-resistance rates. Phenotypic methods, i.e. culture-based AST, are commonly used in high-income countries to confirm susceptibility of new cases of tuberculosis. They are also used to detect resistance in tuberculosis cases with risk factors, in combination with genotypic tests. In low-income countries, genotypic methods screening hot-spot mutations known to confer resistance were found to be easier to perform because they avoid the culture and biosafety constraint. Given that genotypic tests can rapidly detect the prominent mechanisms of resistance, such as the rpoB mutation for rifampicin resistance, we are facing new challenges with the observation of false-resistance (mutations not conferring resistance) and false-susceptibility (mutations different from the common mechanism) results. Phenotypic and genotypic approaches are therefore complementary for obtaining a high sensitivity and specificity for detecting drug resistances and susceptibilities to accurately predict MDR/XDR cure and to gather relevant data for resistance surveillance. Although AST-MTB was established in the 1960s, there is no consensus reference method for MIC determination against which the numerous AST-MTB techniques can be compared. This information is necessary for assessing in vitro activity and setting breakpoints for future anti-tuberculosis agents.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Schön T, Miotto P, Köser CU, et al. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin Microbiol Infect. 2016. PMID: 27810467. doi:10.1016/j.cmi.2016.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。